Efficacy of NB-UVB and azathioprine combination in the therapy of nonsegmental vitiligo
- Authors: Vovdenko K.A.1, Khafizova A.A.2, Lomonosov K.M.1
-
Affiliations:
- I.M. Sechenov First Moscow State Medical University (Sechenov University)
- Lomonosov Moscow State University
- Issue: Vol 25, No 4 (2022)
- Pages: 269-278
- Section: DERMATOLOGY
- URL: https://rjsvd.com/1560-9588/article/view/111578
- DOI: https://doi.org/10.17816/dv111578
- ID: 111578
Cite item
Abstract
BACKGROUND: Vitiligo is a multifactorial acquired disease characterized by the appearance of depigmented, clearly delineated patches, on various areas on the skin. Narrowband Ultraviolet B Therapy is a first-line therapy for nonsegmental vitiligo. At the same time, it often takes at least 6 months to achieve optimal results, which is not always convenient for patients, brings additional financial costs of treatment. Therefore, in most cases to reduce the number of phototherapy sessions requires the use of additional drugs aimed at stopping the progression of the process and with a minimal spectrum of side effects.
AIM: to compare the effectiveness of azathioprine in combination with NB-UVB and NB-UVB monotherapy in progressive non-segmental vitiligo.
MATERIALS AND METHODS: The study included 60 patients with advanced non-segmental vitiligodivided into two groups of 30 people in each. Group A patients received therapy with azathioprine in combination with NB-UVB, and Group B patients ― NB-UVB monotherapy. VASI (Vitiligo Area Scoring Index) and DLQI (Dermatology Life Quality Index) were used for all patients to evaluate therapy efficacy.
RESULTS: All 60 patients diagnosed with nonsegmental progressive vitiligo completed the study and were included in the final analysis. Among patients who received the combined therapy protocol of azathioprine combined with narrowband phototherapy, a statistically more significant reduction in the severity and prevalence of the skin process was noted compared to the group of patients who received NB-UVB alone. More significant arresting of disease progression was noticed: in group A, among 30 patients, only 4 patients developed new lesions of vitiligo within 6 months of therapy, and in group B ― in 11 out of 30 patients. Group A patients showed a more significant reduction of VASI and DLQI compared to the control group.
CONCLUSION: Thus, the combination of NB-UVB and azathioprine in the treatment of non-segmental vitiligo showed great efficacy in arresting and reducing of the disease activity, prevalence and severity of vitiligo. Azathioprine is well tolerated by patients and has a low spectrum of side effects, which allows its successful use to stabilize vitiligo and stimulate repigmentation of foci.
Full Text
About the authors
Kseniia A. Vovdenko
I.M. Sechenov First Moscow State Medical University (Sechenov University)
Author for correspondence.
Email: Vovdenkoksenia@ya.ru
ORCID iD: 0000-0003-1415-3940
SPIN-code: 8315-2175
Graduate Student
Russian Federation, MoscowAinur A. Khafizova
Lomonosov Moscow State University
Email: aya.khafizova@gmail.com
ORCID iD: 0000-0003-4764-6792
SPIN-code: 8282-5488
Cand. Sci. (Biol.)
Russian Federation, MoscowKonstantin M. Lomonosov
I.M. Sechenov First Moscow State Medical University (Sechenov University)
Email: lamclinic@yandex.ru
ORCID iD: 0000-0002-4580-6193
SPIN-code: 4784-9730
MD, Dr. Sci. (Med.), Professor
Russian Federation, MoscowReferences
- Ezzedine K, Eleftheriadou V, Whitton M, van Geel N. Vitiligo. Lancet. 2015;386(9988):74–84. doi: 10.1016/S0140-6736(14)60763-7
- Ezzedine K, Grimes PE, Meurant JM, et al. Living with vitiligo: results from a national survey indicate differences between skin phototypes. Br J Dermatol. 2015;173(2):607–609. doi: 10.1111/bjd.13839
- Simons RE, Zevy DL, Jafferany M. Psychodermatology of vitiligo: psychological impact and consequences. Dermatol Ther. 2020;33(3):e13418. doi: 10.1111/dth.13418
- Sarkar S, Sarkar T, Sarkar A, et al. Vitiligo and psychiatric morbidity: a profile from a vitiligo clinic of a rural-based tertiary care center of Eastern India. Indian J Dermatol. 2018;63(4):281–284. doi: 10.4103/ijd.IJD_142_18
- Sangma LN, Nath J, Bhagabati D. Quality of life and psychological morbidity in vitiligo patients: a study in a teaching hospital from north-East India. Indian J Dermatol. 2015;60(2):142–146. doi: 10.4103/0019-5154.152508
- Taieb A, Alomar A, Böhm M, et al. Guidelines for the management of vitiligo: the European Dermatology Forum consensus. Br J Dermatol. 2013;168(1):5–19. doi: 10.1111/j.1365-2133.2012.11197.x
- Chavez-Alvarez S, Herz-Ruelas M, Villarreal-Martinez A, et al. Azathioprine: its uses in dermatology. An Bras Dermatol. 2020;95(6):731–736. doi: 10.1016/j.abd.2020.05.003
- Okovity SV. Clinical pharmacology of immunosuppressants. Rev Clin Pharmacol Drug Therapy. 2003;2(2):2–34. (In Russ).
- Kubelis-López DE, Zapata-Salazar NA, Said-Fernández SL, et al. Updates and new medical treatments for vitiligo (Review). Exp Ther Med. 2021;22(2):797. doi: 10.3892/etm.2021.10229
- Norris DA, Kissinger RM, Naughton GM, et al. Evidence for immunologic mechanisms in human vitiligo: patients’ sera induce damage to human melanocytes in vitro by complement-mediated damage and antibody-dependent cellular cytotoxicity. J Invest Dermatol. 1988;90(6):783–789. doi: 10.1111/1523-1747.ep12461505
- Iannella G, Greco A, Didona D, et al. Vitiligo: Pathogenesis, clinical variants and treatment approaches. Autoimmun Rev. 2016;15(4):335–343. doi: 10.1016/j.autrev.2015.12.006
- Olisova OY, Andreeva EV. Once more about hyperpigmentation. Russ J Skin Venereal Diseases. 2014;17(2):20–24. (In Russ). doi: 10.17816/dv36849
- Anbar TS, Hegazy RA, Picardo M, et al. Beyond vitiligo guidelines: combined stratified/personalized approaches for the vitiligo patient. Exp Dermatol. 2014;23(4):219–223. doi: 10.1111/exd.12344
- Whitton ME, Pinart M, Batchelor J, et al. Interventions for vitiligo. Cochrane Database Syst Rev. 2015;(2):CD003263. doi: 10.1002/14651858.CD003263.pub5
- Olisova OY. Teplyuk NP, Pinegin VB. Modern methodes of psoriasis treatment. Russ J Med. 2015;23(9):483–486. (In Russ).
- Bae JM, Jung HM, Hong BY, et al. Phototherapy for vitiligo: a systematic review and meta-analysis. JAMA Dermatol. 2017;153(7):666–674. doi: 10.1001/jamadermatol.2017.0002
- Radmanesh M, Saedi K. The efficacy of combined PUVA and low-dose azathioprine for early and enhanced repigmentation in vitiligo patients. J Dermatolog Treat. 2006;17(3):151–153. doi: 10.1080/09546630600791442
- Madarkar M, Ankad B, Manjula R. Comparative study of safety and efficacy of oral betamethasone pulse therapy and azathioprine in vitiligo. Clin Dermatology Rev. 2019;3(2):121–125. doi: 10.4103/CDR.CDR_13_18